A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

Exclusion Criteria

• •Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
• •Concurrent enrollment in another clinical study
• •Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals
• •Exposure to an anti-IgE monoclonal antibodies (MAb) within 12 months prior to Screening
• •Positive drug screen at Screening or Day -1. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids, and benzodiazepines
• •History of regular alcohol abuse within 12 months prior to Screening
• •History of sensitivity to any component of the investigational product formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation
• •Subjects with abnormal liver function test values (aspartate transaminase \[AST\] and alanine transaminase \[ALT\]) at Screening as defined as follows: a) Liver function test values \>= 1.5 times upper limit of normal (ULN)
• •Unwillingness or inability to follow the procedures outlined in the protocol
• •Positive test or history of hepatitis B or positive hepatitis C
• •Positive test or history of human immunodeficiency virus (HIV) or subject is known to be HIV seropositive
• •History of cancer, with the exception of basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success
• •Women who are pregnant, breastfeeding, or lactating
• •Plans to donate blood during the study period
• •Hyper-IgE syndrome or bronchopulmonary aspergillosis
• •Prior history of Immune Complex Disease or type 3 hypersensitivity reactions to MAb administration
• •Known history of prior infusion reaction to MAb administration
• •History of untreated parasitic/helminthic infection within 6 months prior to Screening
• •Uses any of the following medications: a) Oral corticosteroids b) Medium to high dose Immunocorticosteroids (ICS)/ long-acting beta agonists (LABA) c) Immunosuppressives d) Beta blockers
• •If receiving allergy immunotherapy, must be on stable dose for 3 months. Must not receive allergy immunotherapy within 7 days of investigational product administration.